Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
A(H1N1)pdm09
35%
Antiviral Drugs
24%
Care Provision
32%
Chlamydia
48%
Chlamydia Trachomatis Infection
32%
Clearance Rate
32%
Confidence Interval
22%
Contact Diary
22%
Contact Pattern
29%
Cost-effectiveness
77%
COVID-19
67%
COVID-19 Pandemic
27%
Critical Care
32%
Cross-immunity
29%
Drug Resistance
25%
Economic Evaluation
32%
Epidemiological Characteristics
24%
Epidemiology
56%
European Countries
26%
Great Britain
32%
Health Care Services
37%
Infection Rate
26%
Influenza
37%
Influenza Pandemic
32%
Intensive Care Unit
28%
Latent Tuberculosis Infection
41%
Low Burden
48%
Mathematical Model
27%
Mathematical Modeling
32%
Migrants
32%
Molecular Diagnostics
32%
Mycoplasma Genitalium
32%
Natural History
25%
Pandemic Influenza Virus
51%
Primary Care
22%
Public Health Impact
32%
Quality-adjusted Life Years
25%
Reassortment
32%
Risk Behavior
29%
School Closure
48%
Seasonal Influenza
24%
Sex Work
23%
Sexually Transmitted Infections
36%
Surveillance Data
41%
Transmission Dynamics
64%
Tuberculosis
75%
Tuberculosis Diagnosis
32%
United Kingdom
48%
Vaccination
64%
Whole Genome Sequencing
24%
Medicine and Dentistry
2009 H1N1 Influenza
37%
Acute HIV Infection
16%
Antibiotic Resistance
16%
Antiviral Drug
16%
Chlamydia Infection
16%
Chlamydiae
25%
Cluster Randomized Trial
16%
Cohort Analysis
19%
Cost-Effectiveness Analysis
82%
COVID-19
44%
Diagnostic Testing
16%
Drug Resistance
16%
Dynamic Modeling
16%
Emergency Department
16%
Gonorrhea
19%
Health Care Cost
100%
Health Service
34%
High Risk Behavior
20%
Household
32%
Human Immunodeficiency Virus
22%
Infection
43%
Influenza A
16%
Intensive Care
35%
Intensive Care Unit
48%
Interferon Gamma Release Assay
18%
Latent Tuberculosis
35%
Lymphogranuloma Venereum
16%
Men Who Have Sex with Men
18%
Meta-Analysis
16%
Molecular Diagnosis
16%
Mycoplasma genitalium
32%
Observational Study
21%
Pandemic
16%
Pandemic Influenza
48%
Patient Referral
16%
Pelvic Inflammatory Disease
23%
Prenatal Care
16%
Primary Health Care
42%
Public Health
66%
Quality Adjusted Life Year
28%
Randomized Controlled Trial
18%
Recurrent Infection
16%
Reinfection
15%
Rifapentine
16%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Systematic Review
16%
Targeted Therapy
16%
Tuberculosis Diagnosis
16%
Urethritis
21%
Whole Genome Sequencing
21%
